Cargando…
Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy
Preclinical and clinical studies have suggested that expression of ribonucleotide reductase regulatory subunit M1 (RRM1) and excision repair cross-complementation group 1 (ERCC1) is associated with resistance to gemcitabine and cisplatin, respectively. We evaluated the significance of RRM1 and ERCC1...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4511592/ https://www.ncbi.nlm.nih.gov/pubmed/26200905 http://dx.doi.org/10.1371/journal.pone.0133371 |
_version_ | 1782382360920064000 |
---|---|
author | Kim, Miso Ku, Ja Hyeon Kwak, Cheol Kim, Hyeon Hoe Lee, Eunsik Keam, Bhumsuk Kim, Tae Min Heo, Dae Seog Lee, Se-Hoon Moon, Kyung Chul |
author_facet | Kim, Miso Ku, Ja Hyeon Kwak, Cheol Kim, Hyeon Hoe Lee, Eunsik Keam, Bhumsuk Kim, Tae Min Heo, Dae Seog Lee, Se-Hoon Moon, Kyung Chul |
author_sort | Kim, Miso |
collection | PubMed |
description | Preclinical and clinical studies have suggested that expression of ribonucleotide reductase regulatory subunit M1 (RRM1) and excision repair cross-complementation group 1 (ERCC1) is associated with resistance to gemcitabine and cisplatin, respectively. We evaluated the significance of RRM1 and ERCC1 expression to predict tumor response to gemcitabine plus platinum chemotherapy (GP) and survival in advanced UC. We retrospectively collected tumor samples and reviewed clinical data of 53 patients with unresectable or metastatic UC, who were treated with first-line GP. RRM1 and ERCC1 expression were measured by immunohistochemistry. Among 53 patients, 12 (22.6%) and 26 (49.1%) patients had tumors that demonstrated a high expression for RRM1 and ERCC1, respectively. Twenty-nine (70.7%) of 41 patients with low RRM1 expression achieved a clinical response (complete + partial responses), but only 3 (25.0%) of 12 patients with high RRM1 expression achieved a clinical response after GP (P=0.007). Nineteen (70.4%) of 27 patients with low ERCC1 expression achieved a clinical response, while 13 (50.0%) of 26 patients with high ERCC1 expression achieved a clinical response (P=0.130). High RRM1 expression was associated with shorter progression free survival and overall survival (PFS P=0.006, OS P=0.006). Multivariate analysis confirmed that patients with high RRM1 expression had a significantly greater risk of progression and death than those with low RRM1 expression. ERCC1 status was not a significant predictor for PFS and OS. RRM1 expression was predictive and prognostic of clinical outcome in advanced UC treated with gemcitabine plus platinum combination chemotherapy. |
format | Online Article Text |
id | pubmed-4511592 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-45115922015-07-24 Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy Kim, Miso Ku, Ja Hyeon Kwak, Cheol Kim, Hyeon Hoe Lee, Eunsik Keam, Bhumsuk Kim, Tae Min Heo, Dae Seog Lee, Se-Hoon Moon, Kyung Chul PLoS One Research Article Preclinical and clinical studies have suggested that expression of ribonucleotide reductase regulatory subunit M1 (RRM1) and excision repair cross-complementation group 1 (ERCC1) is associated with resistance to gemcitabine and cisplatin, respectively. We evaluated the significance of RRM1 and ERCC1 expression to predict tumor response to gemcitabine plus platinum chemotherapy (GP) and survival in advanced UC. We retrospectively collected tumor samples and reviewed clinical data of 53 patients with unresectable or metastatic UC, who were treated with first-line GP. RRM1 and ERCC1 expression were measured by immunohistochemistry. Among 53 patients, 12 (22.6%) and 26 (49.1%) patients had tumors that demonstrated a high expression for RRM1 and ERCC1, respectively. Twenty-nine (70.7%) of 41 patients with low RRM1 expression achieved a clinical response (complete + partial responses), but only 3 (25.0%) of 12 patients with high RRM1 expression achieved a clinical response after GP (P=0.007). Nineteen (70.4%) of 27 patients with low ERCC1 expression achieved a clinical response, while 13 (50.0%) of 26 patients with high ERCC1 expression achieved a clinical response (P=0.130). High RRM1 expression was associated with shorter progression free survival and overall survival (PFS P=0.006, OS P=0.006). Multivariate analysis confirmed that patients with high RRM1 expression had a significantly greater risk of progression and death than those with low RRM1 expression. ERCC1 status was not a significant predictor for PFS and OS. RRM1 expression was predictive and prognostic of clinical outcome in advanced UC treated with gemcitabine plus platinum combination chemotherapy. Public Library of Science 2015-07-22 /pmc/articles/PMC4511592/ /pubmed/26200905 http://dx.doi.org/10.1371/journal.pone.0133371 Text en © 2015 Kim et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Kim, Miso Ku, Ja Hyeon Kwak, Cheol Kim, Hyeon Hoe Lee, Eunsik Keam, Bhumsuk Kim, Tae Min Heo, Dae Seog Lee, Se-Hoon Moon, Kyung Chul Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy |
title | Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy |
title_full | Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy |
title_fullStr | Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy |
title_full_unstemmed | Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy |
title_short | Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy |
title_sort | predictive and prognostic value of ribonucleotide reductase regulatory subunit m1 and excision repair cross-complementation group 1 in advanced urothelial carcinoma (uc) treated with first-line gemcitabine plus platinum combination chemotherapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4511592/ https://www.ncbi.nlm.nih.gov/pubmed/26200905 http://dx.doi.org/10.1371/journal.pone.0133371 |
work_keys_str_mv | AT kimmiso predictiveandprognosticvalueofribonucleotidereductaseregulatorysubunitm1andexcisionrepaircrosscomplementationgroup1inadvancedurothelialcarcinomauctreatedwithfirstlinegemcitabineplusplatinumcombinationchemotherapy AT kujahyeon predictiveandprognosticvalueofribonucleotidereductaseregulatorysubunitm1andexcisionrepaircrosscomplementationgroup1inadvancedurothelialcarcinomauctreatedwithfirstlinegemcitabineplusplatinumcombinationchemotherapy AT kwakcheol predictiveandprognosticvalueofribonucleotidereductaseregulatorysubunitm1andexcisionrepaircrosscomplementationgroup1inadvancedurothelialcarcinomauctreatedwithfirstlinegemcitabineplusplatinumcombinationchemotherapy AT kimhyeonhoe predictiveandprognosticvalueofribonucleotidereductaseregulatorysubunitm1andexcisionrepaircrosscomplementationgroup1inadvancedurothelialcarcinomauctreatedwithfirstlinegemcitabineplusplatinumcombinationchemotherapy AT leeeunsik predictiveandprognosticvalueofribonucleotidereductaseregulatorysubunitm1andexcisionrepaircrosscomplementationgroup1inadvancedurothelialcarcinomauctreatedwithfirstlinegemcitabineplusplatinumcombinationchemotherapy AT keambhumsuk predictiveandprognosticvalueofribonucleotidereductaseregulatorysubunitm1andexcisionrepaircrosscomplementationgroup1inadvancedurothelialcarcinomauctreatedwithfirstlinegemcitabineplusplatinumcombinationchemotherapy AT kimtaemin predictiveandprognosticvalueofribonucleotidereductaseregulatorysubunitm1andexcisionrepaircrosscomplementationgroup1inadvancedurothelialcarcinomauctreatedwithfirstlinegemcitabineplusplatinumcombinationchemotherapy AT heodaeseog predictiveandprognosticvalueofribonucleotidereductaseregulatorysubunitm1andexcisionrepaircrosscomplementationgroup1inadvancedurothelialcarcinomauctreatedwithfirstlinegemcitabineplusplatinumcombinationchemotherapy AT leesehoon predictiveandprognosticvalueofribonucleotidereductaseregulatorysubunitm1andexcisionrepaircrosscomplementationgroup1inadvancedurothelialcarcinomauctreatedwithfirstlinegemcitabineplusplatinumcombinationchemotherapy AT moonkyungchul predictiveandprognosticvalueofribonucleotidereductaseregulatorysubunitm1andexcisionrepaircrosscomplementationgroup1inadvancedurothelialcarcinomauctreatedwithfirstlinegemcitabineplusplatinumcombinationchemotherapy |